SCHEMBL21422366

SCHEMBL21422366

CON(C)C(=O)c1ccc([C@@H]2CC2C(C)(C)C)c(Cl)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MLYCD O95822 1/20 0.39
SLC6A3 Q01959 3/20 0.37
SIGMAR1 Q99720 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
TSHR P16473 1/20 0.36
CYP2C19 P33261 1/20 0.36
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
SCN9A Q15858 2/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
MCHR1 Q99705 1/20 0.33
ALDH1A1 P00352 1/20 0.33
SLC6A2 P23975 2/20 0.33
SLC6A4 P31645 2/20 0.33
HSP90AA1 P07900 1/20 0.33
HSP90AB1 P08238 1/20 0.33
OPRM1 P35372 1/20 0.32
OPRD1 P41143 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21407891 1.00 MLYCD (0.39) MLYCDSLC6A3SIGMAR1CYP1A2CYP3A4
SCHEMBL21407827 0.82 PDK1 (0.45) SLC6A3CYP1A2CYP3A4CYP2D6TSHR
SCHEMBL21422375 0.82 PDK1 (0.45) SLC6A3CYP1A2CYP3A4CYP2D6TSHR
SCHEMBL22878622 0.80 SLC6A3 (0.40) MLYCDSLC6A3SIGMAR1CYP1A2CYP3A4
SCHEMBL24055157 0.80 CHRNA1 (0.43) MEN1KMT2ASCN9ASMN1; SMN2SLC6A4
SCHEMBL21407844 0.80 CHRNA1 (0.43) MEN1KMT2ASCN9ASMN1; SMN2SLC6A4
SCHEMBL21407909 0.80 TSHR (0.47) SLC6A3TSHRMEN1KMT2ASCN9A
SCHEMBL21422372 0.80 TSHR (0.47) SLC6A3TSHRMEN1KMT2ASCN9A
SCHEMBL30920055 0.80 CHRNA1 (0.43) MEN1KMT2ASCN9ASMN1; SMN2SLC6A4
SCHEMBL2655175 0.75 SLC6A3 (0.54) MLYCDSLC6A3SIGMAR1CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210363110-A1 4-METHYLDIHYDROPYRIMIDINONE COMPOUNDS AND PHARMACEUTICAL USE THEREOF JAPAN TOBACCO INC. (JP) 2021-11-25 US disclosed
US-20190300488-A1 4-METHYLDIHYDROPYRIMIDINONE COMPOUNDS AND PHARMACEUTICAL USE THEREOF SHIONOGI & CO., LTD. (JP) 2019-10-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210363110-A1 4-METHYLDIHYDROPYRIMIDINONE COMPOUNDS AND PHARMACEUTICAL USE THEREOF RORC, RORB, RORA MLYCD 3437/4885SLC6A3 3675/4885SIGMAR1 850/4885
US-20190300488-A1 4-METHYLDIHYDROPYRIMIDINONE COMPOUNDS AND PHARMACEUTICAL USE THEREOF RORC, RORB, RORA MLYCD 3437/4885SLC6A3 3675/4885SIGMAR1 850/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.